Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ortho-k and 0.01% Atropine Sequential Treatment for Myopia in Children
NCT06667037Active, not recruiting
- Sponsor
- Zhongshan Ophthalmic Center
- Start
- Sep 2024
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Randomised, open-label trial of NVK002 in myopia (2 arms), sponsored by Zhongshan Ophthalmic Center. Primary endpoint: Axial length change at 25 months. Started Sep 2024; status: active, not recruiting.
02
Drugs
NVK002
03
Conditions
myopia
Beyond the preview
Go deeper on NCT06667037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06667037.